Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Actifed Rhume
- Development stage
- Unknown
- Lead developer
- Laboratoires Teriak
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Actifed Rhume is an oral combination medication developed and marketed by the Tunisian pharmaceutical company Teriak for the symptomatic relief of the common cold and allergic rhinitis. It contains two active ingredients: pseudoephedrine hydrochloride and triprolidine hydrochloride. Pseudoephedrine is an indirect sympathomimetic agent that acts on adrenergic receptors to induce vasoconstriction in the nasal mucosa, thereby reducing nasal congestion. Triprolidine is a first-generation H1 antihistamine that blocks histamine H1 receptors, effectively reducing allergic symptoms such as sneezing, rhinorrhea, and itchy, watery eyes. The medication is typically administered as scored tablets containing 60 mg of pseudoephedrine and 2.5 mg of triprolidine.
- Brand names
- Actifed Rhume
- Other names
- pseudoephedrine + triprolidinePSEUDOEPHEDRINE+TRIPROLIDINE
02
Targets
HRH1 (Histamine H1 Receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on Actifed Rhume.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Actifed Rhume.